Valchlor Executive Briefing — Week Ending 28 Aug 2026

1. Headline

9 inconsistency flags were identified across 63 AI responses, including conflicting guidance on contraindications, boxed warnings, pregnancy/lactation, and infection risk. This is a baseline week with no prior-week comparison, but the immediate concern is not competitor pressure: it is unreliable product identity, indication, and safety guidance across answer variants.

2. This week at a glance

Additional signal: 11 responses used overclaim-related language, and 56 included hedging/disclaimer language, indicating answers are often cautious but not consistently accurate.

3. Trajectory

Only one week of history is available, so there is no defensible trend yet on safety consistency, competitor visibility, or message improvement. The current baseline is nevertheless material: 9 flags across 9 questions, with no competitor brands appearing. Future weeks should establish whether the problem is persistent or an initial data-quality spike.

4. Where the risk actually is

• Broken, infected, oozing skin or active eczema: only 1 of 7 answer variants included the contraindication; 6 omitted it. A patient could receive an apparently permissive answer despite another answer correctly advising against use.
• Switching therapies: variants inconsistently included contraindications, infection risk, pregnancy/lactation considerations, allergic reactions, and boxed-warning content. This creates an uneven counseling standard for a clinically consequential decision.
• Application and dosing: answers not only varied on safety details, but several misidentified Valchlor as valrubicin, verapamil, or other products, and gave conflicting indications and schedules. This is a higher-order risk than simple omission: users may receive instructions for the wrong medicine.

The molluscum question also split between “do not use/not standard” and “yes, sometimes used,” reinforcing off-label ambiguity.

5. Recommended actions

1. Correct the authoritative product knowledge source immediately — Medical Affairs/Regulatory. Lock Valchlor’s identity, active ingredient, concentration, indication, application instructions, contraindications, and exposure-response guidance into approved reference content. This addresses repeated product and indication substitutions.
2. Create a safety-critical answer standard — Medical Affairs/PV. Require consistent treatment of contraindications, boxed-warning content, pregnancy/lactation, infection risk, eye/mouth exposure, and allergic reactions. Prioritize the 9 inconsistency flags.
3. Publish structured, machine-readable PI and FAQ content — Content/SEO with Regulatory review. Use explicit headings and short answer blocks for broken skin, dosing/application, accidental exposure, and off-label questions to reduce omission and hallucination.
4. Add an escalation and monitoring dashboard — Digital/AI monitoring with PV and Medical Affairs. Track identity errors and inconsistency rates separately from general mention counts; set review triggers for any answer that recommends use for an unapproved condition.
5. Avoid promotional “strength” framing — Marketing/Medical Affairs. Replace it with indication-, evidence-, and tolerability-based language, addressing the 11 overclaim-language detections.

Named model attribution is not available in the supplied data; findings refer to answer variants rather than specific models.